Quince Therapeutics (QNCX) officer awarded multi-million share option grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Quince Therapeutics, Inc. director and Chief Corp. Affairs Officer Brigette Roberts reported receiving multiple employee stock option awards for Quince common stock. On May 18, 2026, she was granted options covering several blocks of shares, including 6,837,319 options with an exercise price of $0.84 per share and additional grants such as 2,070,107 options at $0.09 per share, all classified as awards rather than market purchases or sales.
Footnotes explain these options were received in exchange for prior Orphai Therapeutics options under an Agreement and Plan of Merger involving Quince and Orphai entities. One option block begins vesting on May 21, 2026 in 36 equal monthly installments, conditioned on her continued service with the company. The filing shows only acquisitions of derivative awards, with no open-market stock trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Roberts Brigette
Role
Chief Corp. Affairs Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 34,675 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 228,855 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 124,830 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 69,350 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 362,092 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 133,615 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 2,070,107 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 6,837,319 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 6,837,319 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 34,675 shares (Direct, null)
Footnotes (1)
- Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai. Immediately exercisable. Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date.
Key Figures
Largest option grant: 6,837,319 options
Second large grant: 2,070,107 options
Additional option blocks: Amounts from 34,675 to 693,50 options
+3 more
6 metrics
Largest option grant
6,837,319 options
Employee Stock Option at $0.84 exercise price, expiring May 11, 2036
Second large grant
2,070,107 options
Employee Stock Option at $0.09 exercise price, expiring March 15, 2036
Additional option blocks
Amounts from 34,675 to 693,50 options
Smaller employee stock option grants at $0.09 exercise price, expiring 2031–2034
Orphai $0.06 options exchanged
330,000–9,859,148 shares
Footnotes describe Orphai options over various amounts at $0.06 or $0.58 exchanged
Vesting schedule
36 monthly installments
One option begins vesting May 21, 2026, subject to continued service
Expiration range
2031–2036 expirations
Option grants carry long-dated expiration dates from 2031 to 2036
Key Terms
Employee Stock Option (Right to Buy), Agreement and Plan of Merger, Continued Service, 2026 Stock Incentive Plan, +1 more
5 terms
Employee Stock Option (Right to Buy) financial
"security_title: Employee Stock Option (Right to Buy)"
Agreement and Plan of Merger regulatory
"pursuant to an Agreement and Plan of Merger, dated May 17, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Continued Service financial
"subject to the Reporting Person's Continued Service with the Issuer"
2026 Stock Incentive Plan financial
"as defined in the Orphai's 2026 Stock Incentive Plan"
employee stock option awards financial
"Received in exchange for stock options to acquire an aggregate of"
FAQ
What insider transaction did Quince Therapeutics (QNCX) report for Brigette Roberts?
Quince Therapeutics reported that Brigette Roberts received multiple employee stock option awards on May 18, 2026. These derivative awards give her the right to buy Quince common stock at preset prices, but do not represent any open-market share purchases or sales.
How many Quince Therapeutics (QNCX) options were granted to Brigette Roberts?
The filing shows several option grants, including 6,837,319 employee stock options and another block of 2,070,107 options. Each block has its own terms, exercise price, and expiration date, all reported as awards rather than market transactions in Quince common stock.
What are the exercise prices of Brigette Roberts’ Quince (QNCX) option awards?
Key option blocks were granted with exercise prices such as $0.84 per share and $0.09 per share. These prices represent the amounts Roberts must pay per share if she later exercises each option to acquire Quince common stock.
When do Brigette Roberts’ Quince Therapeutics (QNCX) options expire?
The reported options have long-dated expirations, with examples including dates like May 11, 2036 and March 15, 2036. Each grant carries its own specific expiration date, defining the latest point at which the options may be exercised under their terms.
How do the Orphai Therapeutics options relate to this Quince (QNCX) Form 4?
Footnotes state the Quince options were received in exchange for Orphai Therapeutics options under a merger agreement. Prior Orphai options over various share amounts and a $0.06 or $0.58 exercise price were converted into Quince options as part of that transaction.
How do Brigette Roberts’ Quince (QNCX) options vest over time?
One option block begins vesting on May 21, 2026 in 36 equal monthly installments. Vesting is conditioned on her continued service with the issuer, meaning she earns the right to exercise additional portions of the option each month she remains employed.